Novo Nordisk A/S said its high-dose version of blockbuster Wegovy has been cleared by the European Union’s drug advisory board, opening the way for use of a shot that delivers more weight loss than ...

Novo Nordisk said on Friday the European Medicines Agency's committee has issued a positive opinion for a 7.2 mg dose of weight-loss drug Wegovy, providing an option for greater weight loss.

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Ozempic has been approved for type-2 diabetes, while Novo Nordisk’s other global blockbuster Wegovy is targeted at obesity.

By Maggie Fick LONDON, Dec 11 (Reuters) - Zealand Pharma plans to launch five obesity and related drugs by 2030 as the Danish ...

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

In an interview, Novo Nordisk India’s managing director Vikrant Shrotriya discusses the launch of Ozempic, the company’s ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability ...

A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed promising results in new data released Thursday by its maker, Eli Lilly.

New weight-loss drug can burn fat while preserving muscle and appetite, scientists say - Researchers say new compound ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...